Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women
Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability 'trait' that exists independently...
Gespeichert in:
Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2005-05, Vol.30 (5), p.1028-1032 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1032 |
---|---|
container_issue | 5 |
container_start_page | 1028 |
container_title | Neuropsychopharmacology (New York, N.Y.) |
container_volume | 30 |
creator | STEIGER, Howard RICHARDSON, Jodie ISRAEL, Mimi NG YING KIN, N. M. K BRUCE, Kenneth MANSOUR, Sandra PARENT, Anne Marie |
description | Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability 'trait' that exists independently of active eating-disorder manifestations. We compared women with full-blown BN (BN; n=22), BN in remission (BN-R; n=11), and no eating or psychiatric disturbances (n=22) on measures of platelet [(3)H]paroxetine binding, eating symptoms and psychopathology. The BN-R group showed normal-range scores on eating and psychopathological symptoms, but reductions in density (B(max)) of binding sites for paroxetine similar to those obtained in the actively ill women. Both BN groups had substantially lower B(max) than did healthy controls. Our results corroborate other findings indicating recovered BN patients to have anomalous 5-HT functioning. While such effects could represent a lasting 'injury' to the system, reported covariations between personality traits and 5-HT indices in BN encourage us to favor the argument that some alterations of 5-HT activity (in this case, consistent with reduced transporter activity) represent a 'trait' associated with the risk of developing BN and/or associated psychopathology. |
doi_str_mv | 10.1038/sj.npp.1300693 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_225233706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>971203411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-bf16920cddd2a7d73cf0f45311d948ff5c58701eb0eef8fc394ccb89456630ad3</originalsourceid><addsrcrecordid>eNpF0N1L5DAUBfAgis6qr765hIV97HjTpG366NeqICh-g0jJJDdLhjadTVLQ_34rU5in-_K758Ah5IjBnAGXJ3E596vVnHGAsuZbZMYqAVnJxds2mYGsecY4f9sjP2JcArCiKuUu2WOFFAxkNSMvD2gGjYZeoI8ufdHe0vtWJWwxZWfOG-f_0keXMFLbB_rOrz_uVeg_MTmP1Hn6gJ1LaQw4G1rXOU1f-w79Admxqo14ON198vzn8un8Oru9u7o5P73NtGB5yhaWlXUO2hiTq8pUXFuwouCMmVpIawtdyAoYLgDRSqt5LbReyFoUZclBGb5Pfq1zV6H_N2BMzbIfgh8rmzwvcs4rKEc0XyMd-hgD2mYVXKfCV8Og-V6xictmXLGZVhwffk6pw6JDs-HTbCP4PQEVtWptUF67uHFlJXguYXTHa-dVGgJuwFT0H_90hQY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225233706</pqid></control><display><type>article</type><title>Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>STEIGER, Howard ; RICHARDSON, Jodie ; ISRAEL, Mimi ; NG YING KIN, N. M. K ; BRUCE, Kenneth ; MANSOUR, Sandra ; PARENT, Anne Marie</creator><creatorcontrib>STEIGER, Howard ; RICHARDSON, Jodie ; ISRAEL, Mimi ; NG YING KIN, N. M. K ; BRUCE, Kenneth ; MANSOUR, Sandra ; PARENT, Anne Marie</creatorcontrib><description>Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability 'trait' that exists independently of active eating-disorder manifestations. We compared women with full-blown BN (BN; n=22), BN in remission (BN-R; n=11), and no eating or psychiatric disturbances (n=22) on measures of platelet [(3)H]paroxetine binding, eating symptoms and psychopathology. The BN-R group showed normal-range scores on eating and psychopathological symptoms, but reductions in density (B(max)) of binding sites for paroxetine similar to those obtained in the actively ill women. Both BN groups had substantially lower B(max) than did healthy controls. Our results corroborate other findings indicating recovered BN patients to have anomalous 5-HT functioning. While such effects could represent a lasting 'injury' to the system, reported covariations between personality traits and 5-HT indices in BN encourage us to favor the argument that some alterations of 5-HT activity (in this case, consistent with reduced transporter activity) represent a 'trait' associated with the risk of developing BN and/or associated psychopathology.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/sj.npp.1300693</identifier><identifier>PMID: 15841087</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Adult ; Antidepressive Agents, Second-Generation - blood ; Antidepressive Agents, Second-Generation - therapeutic use ; Binding Sites ; Biological and medical sciences ; Blood Platelets - metabolism ; Bulimia - blood ; Bulimia - drug therapy ; Bulimia - psychology ; Cathartics ; Diuretics ; Female ; Humans ; Medical sciences ; Neuropharmacology ; Paroxetine - blood ; Paroxetine - therapeutic use ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Substance-Related Disorders - blood ; Substance-Related Disorders - psychology ; Vomiting - blood ; Vomiting - psychology</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2005-05, Vol.30 (5), p.1028-1032</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Nature Publishing Group May 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-bf16920cddd2a7d73cf0f45311d948ff5c58701eb0eef8fc394ccb89456630ad3</citedby><cites>FETCH-LOGICAL-c412t-bf16920cddd2a7d73cf0f45311d948ff5c58701eb0eef8fc394ccb89456630ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16743280$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15841087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEIGER, Howard</creatorcontrib><creatorcontrib>RICHARDSON, Jodie</creatorcontrib><creatorcontrib>ISRAEL, Mimi</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BRUCE, Kenneth</creatorcontrib><creatorcontrib>MANSOUR, Sandra</creatorcontrib><creatorcontrib>PARENT, Anne Marie</creatorcontrib><title>Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability 'trait' that exists independently of active eating-disorder manifestations. We compared women with full-blown BN (BN; n=22), BN in remission (BN-R; n=11), and no eating or psychiatric disturbances (n=22) on measures of platelet [(3)H]paroxetine binding, eating symptoms and psychopathology. The BN-R group showed normal-range scores on eating and psychopathological symptoms, but reductions in density (B(max)) of binding sites for paroxetine similar to those obtained in the actively ill women. Both BN groups had substantially lower B(max) than did healthy controls. Our results corroborate other findings indicating recovered BN patients to have anomalous 5-HT functioning. While such effects could represent a lasting 'injury' to the system, reported covariations between personality traits and 5-HT indices in BN encourage us to favor the argument that some alterations of 5-HT activity (in this case, consistent with reduced transporter activity) represent a 'trait' associated with the risk of developing BN and/or associated psychopathology.</description><subject>Adult</subject><subject>Antidepressive Agents, Second-Generation - blood</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - metabolism</subject><subject>Bulimia - blood</subject><subject>Bulimia - drug therapy</subject><subject>Bulimia - psychology</subject><subject>Cathartics</subject><subject>Diuretics</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Paroxetine - blood</subject><subject>Paroxetine - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Substance-Related Disorders - blood</subject><subject>Substance-Related Disorders - psychology</subject><subject>Vomiting - blood</subject><subject>Vomiting - psychology</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpF0N1L5DAUBfAgis6qr765hIV97HjTpG366NeqICh-g0jJJDdLhjadTVLQ_34rU5in-_K758Ah5IjBnAGXJ3E596vVnHGAsuZbZMYqAVnJxds2mYGsecY4f9sjP2JcArCiKuUu2WOFFAxkNSMvD2gGjYZeoI8ufdHe0vtWJWwxZWfOG-f_0keXMFLbB_rOrz_uVeg_MTmP1Hn6gJ1LaQw4G1rXOU1f-w79Admxqo14ON198vzn8un8Oru9u7o5P73NtGB5yhaWlXUO2hiTq8pUXFuwouCMmVpIawtdyAoYLgDRSqt5LbReyFoUZclBGb5Pfq1zV6H_N2BMzbIfgh8rmzwvcs4rKEc0XyMd-hgD2mYVXKfCV8Og-V6xictmXLGZVhwffk6pw6JDs-HTbCP4PQEVtWptUF67uHFlJXguYXTHa-dVGgJuwFT0H_90hQY</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>STEIGER, Howard</creator><creator>RICHARDSON, Jodie</creator><creator>ISRAEL, Mimi</creator><creator>NG YING KIN, N. M. K</creator><creator>BRUCE, Kenneth</creator><creator>MANSOUR, Sandra</creator><creator>PARENT, Anne Marie</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20050501</creationdate><title>Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women</title><author>STEIGER, Howard ; RICHARDSON, Jodie ; ISRAEL, Mimi ; NG YING KIN, N. M. K ; BRUCE, Kenneth ; MANSOUR, Sandra ; PARENT, Anne Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-bf16920cddd2a7d73cf0f45311d948ff5c58701eb0eef8fc394ccb89456630ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Antidepressive Agents, Second-Generation - blood</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - metabolism</topic><topic>Bulimia - blood</topic><topic>Bulimia - drug therapy</topic><topic>Bulimia - psychology</topic><topic>Cathartics</topic><topic>Diuretics</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Paroxetine - blood</topic><topic>Paroxetine - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Substance-Related Disorders - blood</topic><topic>Substance-Related Disorders - psychology</topic><topic>Vomiting - blood</topic><topic>Vomiting - psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEIGER, Howard</creatorcontrib><creatorcontrib>RICHARDSON, Jodie</creatorcontrib><creatorcontrib>ISRAEL, Mimi</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BRUCE, Kenneth</creatorcontrib><creatorcontrib>MANSOUR, Sandra</creatorcontrib><creatorcontrib>PARENT, Anne Marie</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEIGER, Howard</au><au>RICHARDSON, Jodie</au><au>ISRAEL, Mimi</au><au>NG YING KIN, N. M. K</au><au>BRUCE, Kenneth</au><au>MANSOUR, Sandra</au><au>PARENT, Anne Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>30</volume><issue>5</issue><spage>1028</spage><epage>1032</epage><pages>1028-1032</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability 'trait' that exists independently of active eating-disorder manifestations. We compared women with full-blown BN (BN; n=22), BN in remission (BN-R; n=11), and no eating or psychiatric disturbances (n=22) on measures of platelet [(3)H]paroxetine binding, eating symptoms and psychopathology. The BN-R group showed normal-range scores on eating and psychopathological symptoms, but reductions in density (B(max)) of binding sites for paroxetine similar to those obtained in the actively ill women. Both BN groups had substantially lower B(max) than did healthy controls. Our results corroborate other findings indicating recovered BN patients to have anomalous 5-HT functioning. While such effects could represent a lasting 'injury' to the system, reported covariations between personality traits and 5-HT indices in BN encourage us to favor the argument that some alterations of 5-HT activity (in this case, consistent with reduced transporter activity) represent a 'trait' associated with the risk of developing BN and/or associated psychopathology.</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>15841087</pmid><doi>10.1038/sj.npp.1300693</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0893-133X |
ispartof | Neuropsychopharmacology (New York, N.Y.), 2005-05, Vol.30 (5), p.1028-1032 |
issn | 0893-133X 1740-634X |
language | eng |
recordid | cdi_proquest_journals_225233706 |
source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Antidepressive Agents, Second-Generation - blood Antidepressive Agents, Second-Generation - therapeutic use Binding Sites Biological and medical sciences Blood Platelets - metabolism Bulimia - blood Bulimia - drug therapy Bulimia - psychology Cathartics Diuretics Female Humans Medical sciences Neuropharmacology Paroxetine - blood Paroxetine - therapeutic use Pharmacology. Drug treatments Psychiatric Status Rating Scales Substance-Related Disorders - blood Substance-Related Disorders - psychology Vomiting - blood Vomiting - psychology |
title | Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T11%3A52%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20Density%20of%20Platelet-Binding%20Sites%20for%20%5B3H%5DParoxetine%20in%20Remitted%20Bulimic%20Women&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=STEIGER,%20Howard&rft.date=2005-05-01&rft.volume=30&rft.issue=5&rft.spage=1028&rft.epage=1032&rft.pages=1028-1032&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/sj.npp.1300693&rft_dat=%3Cproquest_cross%3E971203411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225233706&rft_id=info:pmid/15841087&rfr_iscdi=true |